LV10920B - Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide - Google Patents

Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide Download PDF

Info

Publication number
LV10920B
LV10920B LVP-95-220A LV950220A LV10920B LV 10920 B LV10920 B LV 10920B LV 950220 A LV950220 A LV 950220A LV 10920 B LV10920 B LV 10920B
Authority
LV
Latvia
Prior art keywords
chloro
carboxamide
oxindole
fluoro
lysine salt
Prior art date
Application number
LVP-95-220A
Other languages
English (en)
Latvian (lv)
Other versions
LV10920A (lv
Inventor
Cooper Kelvin
Crawford Thomas Charles
Bruce H Littman
Christopher J Pazoles
Sally G Ruggeri
Keith D Wilner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/007,217 external-priority patent/US5298522A/en
Application filed by Pfizer filed Critical Pfizer
Publication of LV10920A publication Critical patent/LV10920A/xx
Publication of LV10920B publication Critical patent/LV10920B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LVP-95-220A 1993-01-22 1995-07-21 Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide LV10920B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/007,217 US5298522A (en) 1993-01-22 1993-01-22 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
US13827793A 1993-10-18 1993-10-18
PCT/US1994/000096 WO1994016694A1 (fr) 1993-01-22 1994-01-06 Sel de lysine de 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide

Publications (2)

Publication Number Publication Date
LV10920A LV10920A (lv) 1995-12-20
LV10920B true LV10920B (en) 1996-04-20

Family

ID=26676677

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-220A LV10920B (en) 1993-01-22 1995-07-21 Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide

Country Status (27)

Country Link
EP (1) EP0680321B1 (fr)
JP (1) JP2711939B2 (fr)
CN (1) CN1116822A (fr)
AP (1) AP468A (fr)
AT (1) ATE171373T1 (fr)
AU (1) AU671533B2 (fr)
BG (1) BG61966B1 (fr)
BR (1) BR9405661A (fr)
CA (1) CA2153050C (fr)
CZ (1) CZ182895A3 (fr)
DE (1) DE69413518T2 (fr)
DK (1) DK0680321T3 (fr)
DZ (1) DZ1748A1 (fr)
ES (1) ES2122236T3 (fr)
FI (1) FI940309A (fr)
HU (1) HUT69687A (fr)
IL (1) IL108326A0 (fr)
LV (1) LV10920B (fr)
MA (1) MA23095A1 (fr)
NO (1) NO952904L (fr)
NZ (1) NZ261449A (fr)
OA (1) OA10173A (fr)
PL (1) PL309957A1 (fr)
SK (1) SK91395A3 (fr)
UY (1) UY23723A1 (fr)
WO (1) WO1994016694A1 (fr)
YU (1) YU48719B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7503496A (en) * 1995-12-19 1997-07-14 Pfizer Inc. Stable, long acting salts of indole derivatives for the treatment of joint diseases
EP0826685A1 (fr) * 1996-08-21 1998-03-04 Pfizer Inc. Sels de carboxamides stables à effet prolongé destinés au traitement des maladies articulaires
DE10106852A1 (de) * 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US4853409A (en) * 1988-04-13 1989-08-01 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
DE4111306C2 (de) * 1991-04-08 1994-06-01 Mack Chem Pharm Pharmazeutische Zubereitungen, die ein 2-Oxindol-l-carboxamid-derivat enthalten und zur Injektion bestimmt sind
DE4111305C2 (de) * 1991-04-08 1994-12-01 Mack Chem Pharm Pharmazeutische Zubereitung zur rektalen Applikation, die ein 2-Oxindol-l-carboxamid-derivat enthält
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio

Also Published As

Publication number Publication date
DZ1748A1 (fr) 2002-02-17
EP0680321A1 (fr) 1995-11-08
CA2153050A1 (fr) 1994-08-04
ATE171373T1 (de) 1998-10-15
AP9400609A0 (en) 1994-01-31
UY23723A1 (es) 1994-06-28
BG61966B1 (bg) 1998-11-30
DK0680321T3 (da) 1999-06-14
BR9405661A (pt) 1995-11-21
FI940309A0 (fi) 1994-01-21
PL309957A1 (en) 1995-11-13
JP2711939B2 (ja) 1998-02-10
CZ182895A3 (en) 1996-01-17
IL108326A0 (en) 1994-04-12
AU6019894A (en) 1994-08-15
OA10173A (en) 1996-12-18
CA2153050C (fr) 1998-12-29
YU48719B (sh) 1999-07-28
EP0680321B1 (fr) 1998-09-23
LV10920A (lv) 1995-12-20
ES2122236T3 (es) 1998-12-16
CN1116822A (zh) 1996-02-14
MA23095A1 (fr) 1994-10-01
BG99767A (bg) 1996-02-28
FI940309A (fi) 1994-07-23
DE69413518T2 (de) 1999-02-11
NO952904D0 (no) 1995-07-21
DE69413518D1 (en) 1998-10-29
JPH08501109A (ja) 1996-02-06
NZ261449A (en) 1996-08-27
HUT69687A (en) 1995-09-28
WO1994016694A1 (fr) 1994-08-04
AP468A (en) 1996-03-05
AU671533B2 (en) 1996-08-29
HU9400176D0 (en) 1994-05-30
SK91395A3 (en) 1996-12-04
YU2394A (sh) 1996-10-18
NO952904L (no) 1995-07-21

Similar Documents

Publication Publication Date Title
US5298522A (en) 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
JP2012246321A (ja) N−メチル−n−[(1s)−1−フェニル−2−{(3s)−3−ヒドロキシピロリジン−1−イル}エチル]−2,2−ジフェニルアセトアミド
HU226976B1 (en) Use of pirrolidine derivatives having kappa-opium-agonist effect for the preparation of a medicament for treating of inflammatory diseases of the intestine
JPS63107970A (ja) チオラクタム−n−酢酸誘導体
HU193348B (en) Process for producing piroxicam salts of antiflogistic activity
WO1989003682A1 (fr) Derives de dioxyde de benzothiazine
JP2002053557A (ja) アポリポ蛋白a−i産生促進薬
AP468A (en) Lysine salt of 6-chloro-5-fluoro-3(2-thenoyl)-2-oxindole-1- carboxamide.
JPH0629271B2 (ja) ベンゾチアジン―1,1―ジオキシド誘導体及びそれを含有する医薬組成物
JPH11509520A (ja) 鎮痛特性を有する新規のn−アセチル化4−ヒドロキシフェニルアミン誘導体及びそれを含む薬理組成物
KR100556559B1 (ko) 2-(4-(4-(4,5-디클로로-2-메틸이미다졸-1-일)부틸)-1-피페라지닐)-5-플루오로피리미딘, 이것의 제조 방법 및 이것의치료적 용도
JPS63275572A (ja) 1,5−ベンゾチアゼピン誘導体
JP4011780B2 (ja) ジヒドロキノリン誘導体
JPH0228113A (ja) 高尿酸血症改善・治療剤
WO1998003201A1 (fr) Nouvelles compositions medicinales a usage therapeutique
JPH01287023A (ja) 利尿剤